Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein - PubMed (original) (raw)
. 2005 Jun 1;174(11):7179-85.
doi: 10.4049/jimmunol.174.11.7179.
Diana M Truitt, Angelique A C Lemckert, Ronald Vogels, Jerome H H V Custers, Marylyn M Addo, Shahin Lockman, Trevor Peter, Fred W Peyerl, Michael G Kishko, Shawn S Jackson, Darci A Gorgone, Michelle A Lifton, Myron Essex, Bruce D Walker, Jaap Goudsmit, Menzo J E Havenga, Dan H Barouch
Affiliations
- PMID: 15905562
- DOI: 10.4049/jimmunol.174.11.7179
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
Shawn M Sumida et al. J Immunol. 2005.
Abstract
The utility of recombinant adenovirus serotype 5 (rAd5) vector-based vaccines for HIV-1 and other pathogens will likely be limited by the high prevalence of pre-existing Ad5-specific neutralizing Abs (NAbs) in human populations. However, the immunodominant targets of Ad5-specific NAbs in humans remain poorly characterized. In this study, we assess the titers and primary determinants of Ad5-specific NAbs in individuals from both the United States and the developing world. Importantly, median Ad5-specific NAb titers were >10-fold higher in sub-Saharan Africa compared with the United States. Moreover, hexon-specific NAb titers were 4- to 10-fold higher than fiber-specific NAb titers in these cohorts by virus neutralization assays using capsid chimeric viruses. We next performed adoptive transfer studies in mice to evaluate the functional capacity of hexon- and fiber-specific NAbs to suppress the immunogenicity of a prototype rAd5-Env vaccine. Hexon-specific NAbs were remarkably efficient at suppressing Env-specific immune responses elicited by the rAd5 vaccine. In contrast, fiber-specific NAbs exerted only minimal suppressive effects on rAd5 vaccine immunogenicity. These data demonstrate that functionally significant Ad5-specific NAbs are directed primarily against the Ad5 hexon protein in both humans and mice. These studies suggest a potential strategy for engineering novel Ad5 vectors to evade dominant Ad5-specific NAbs.
Similar articles
- Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH. Sumida SM, et al. J Virol. 2004 Mar;78(6):2666-73. doi: 10.1128/jvi.78.6.2666-2673.2004. J Virol. 2004. PMID: 14990686 Free PMC article. - Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Bradley RR, et al. J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9. J Virol. 2012. PMID: 22072776 Free PMC article. - Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Bradley RR, et al. J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9. J Virol. 2012. PMID: 22072746 Free PMC article. - Advances and future challenges in adenoviral vector pharmacology and targeting.
Khare R, Chen CY, Weaver EA, Barry MA. Khare R, et al. Curr Gene Ther. 2011 Aug;11(4):241-58. doi: 10.2174/156652311796150363. Curr Gene Ther. 2011. PMID: 21453281 Free PMC article. Review. - Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.
Daussy CF, Pied N, Wodrich H. Daussy CF, et al. Viruses. 2021 Jun 24;13(7):1221. doi: 10.3390/v13071221. Viruses. 2021. PMID: 34202573 Free PMC article. Review.
Cited by
- Immunity and Protective Efficacy of a Plant-Based Tobacco Mosaic Virus-like Nanoparticle Vaccine against Influenza a Virus in Mice.
Madapong A, Petro-Turnquist EM, Webby RJ, McCormick AA, Weaver EA. Madapong A, et al. Vaccines (Basel). 2024 Sep 26;12(10):1100. doi: 10.3390/vaccines12101100. Vaccines (Basel). 2024. PMID: 39460267 Free PMC article. - Prime-boost immunization with inactivated human adenovirus type 55 combined with an adjuvant enhances neutralizing antibody responses in mice.
Seo SH, Choi JA, Jung DI, Park Y, Yang E, Jung S, Kwon T, Kwon SH, Song M. Seo SH, et al. Virol J. 2024 Sep 16;21(1):220. doi: 10.1186/s12985-024-02491-y. Virol J. 2024. PMID: 39285440 Free PMC article. - The short fiber knobs of human adenovirus in species F elicit cross-neutralizing antibody responses.
Liu Z, Tang G, Peng Y, Lan J, Xian Y, Tian X, Chen D. Liu Z, et al. Heliyon. 2024 Aug 3;10(15):e35783. doi: 10.1016/j.heliyon.2024.e35783. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170224 Free PMC article. - The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.
Wallace R, Bliss CM, Parker AL. Wallace R, et al. Viruses. 2024 Jun 17;16(6):973. doi: 10.3390/v16060973. Viruses. 2024. PMID: 38932265 Free PMC article. Review. - Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews.
Liu X, Li Z, Li X, Zhang X, Zheng Y, Su W, Feng Y, Liu Y, Wu W, Sun X, Wang N, Ye X, Zhou Z, Liu W, He J, Wang W, Qu L, Zhou R, Chen L, Feng L. Liu X, et al. Emerg Microbes Infect. 2024 Dec;13(1):2307513. doi: 10.1080/22221751.2024.2307513. Epub 2024 Feb 1. Emerg Microbes Infect. 2024. PMID: 38240267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources